WHO Pain Ladder Overview
The WHO analgesic ladder is a three-step sequential approach to cancer pain management that starts with non-opioids (Step 1), progresses to weak opioids (Step 2), and advances to strong opioids (Step 3), with adjuvant medications added at any step as needed 1.
The Three Steps
Step 1: Mild Pain
- Non-opioid analgesics (NSAIDs, acetaminophen/paracetamol, dipyrone)
- Add adjuvant medications if indicated (antidepressants, anticonvulsants, neuroleptics)
- NSAIDs are traditionally thought effective for bone metastases, though recent evidence shows equal efficacy for both visceral and somatic pain syndromes 1
Step 2: Moderate Pain
- Weak opioids (primarily tramadol in most settings, though codeine historically used)
- Continue non-opioid analgesics ± adjuvants
- Important caveat: The utility of this step has been questioned, with some suggesting it could be bypassed to move directly from Step 1 to Step 3 1
Step 3: Severe Pain
- Strong opioids (morphine is the gold standard, with other options including hydromorphone, oxycodone, fentanyl)
- Continue non-opioid analgesics ± adjuvants
- Mean effective dose in pediatric studies was 0.034 mg/kg/h IV morphine equivalents 2
Clinical Application and Effectiveness
The WHO ladder achieves adequate pain control in 45-100% of patients across studies, with most reporting 69-90% success rates 1, 3, 4. In one large single-center experience, 87.5% of cancer patients were successfully managed using the ladder approach, with the majority (73.79%) requiring Step 2 treatment 5.
Key Implementation Points
Adjuvant medications are frequently necessary: In clinical practice, 43.5% of patients required anticonvulsants or neuroleptics, and 81.97% used antidepressants alongside ladder medications 5
Opioid monotherapy may be superior to combination therapy: Pediatric data showed lower pain scores and fewer adverse effects with opioid monotherapy compared to opioid plus non-opioid combinations 2. This challenges the traditional approach of always combining medications
Alternative sequencing: Some evidence suggests starting opioids first, then adding NSAIDs later for difficult-to-control pain or when opioid dose escalation causes adverse effects, rather than the traditional bottom-up approach 1
Critical Limitations and Controversies
Despite widespread adoption since 1986, the WHO ladder lacks robust evidence from controlled trials 1, 3, 4. All validation studies have significant methodological flaws including:
- Small sample sizes
- Retrospective designs
- High dropout rates
- Inadequate follow-up
- No comparison groups
Unresolved Questions
- Optimal duration of NSAID use in cancer pain (long-term safety profile never established in randomized trials) 1
- Whether Step 2 is necessary or should be bypassed
- Best indications for different strong opioids and routes of administration
- How to improve opioid response with adjuvants
- The 10-30% of patients who don't achieve adequate relief
Common Pitfalls to Avoid
- Don't rigidly adhere to sequential progression: Patients with severe pain can start directly on Step 3
- Don't automatically combine opioids with non-opioids: Evidence suggests opioid monotherapy may be equally or more effective with fewer side effects 2
- Don't neglect adjuvants: The majority of patients require adjuvant medications for optimal pain control 5
- Don't ignore the 7.5-12% who need invasive techniques: Some patients require nerve blocks, epidurals, or other interventional approaches beyond the ladder 5
Special Considerations for Elderly Patients
Elderly patients require dose adjustments due to altered metabolism and increased risk of gastrointestinal complications, particularly with NSAIDs 6.